# Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

> **NCT02129985** · PHASE4 · UNKNOWN · sponsor: **xiaolong zhao** · enrollment: 100 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Exenatide
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02129985
- **Lead sponsor:** xiaolong zhao
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-02
- **Primary completion:** 2015-06
- **Final completion:** 2015-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-05-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129985, "Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02129985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*